Tumor Necrosis Factor Blocker [EPC]

859175 reported adverse events

Drugs of this class: ADALIMUMAB-ATTO INFLIXIMAB ADALIMUMAB ADALIMUMAB-ADAZ GOLIMUMAB ADALIMUMAB-AQVH ADALIMUMAB-BWWD CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 101856
1 INJECTION SITE PAIN 58454
2 OFF LABEL USE 57813
3 ARTHRALGIA 57481
4 PAIN 52043
5 RHEUMATOID ARTHRITIS 50219
6 INJECTION SITE ERYTHEMA 41723
7 FATIGUE 39532
8 CONDITION AGGRAVATED 35464
9 HEADACHE 31683
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 294 0.9735
1 INJECTION SITE RECALL REACTION 484 0.9719
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 3578 0.9325
3 SWOLLEN JOINT COUNT INCREASED 940 0.8978
4 RHEUMATOID FACTOR POSITIVE 3039 0.8748
5 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1726 0.8366
6 RHEUMATIC FEVER 1175 0.8200
7 PEMPHIGUS 6350 0.7995
8 C-REACTIVE PROTEIN ABNORMAL 3048 0.7787
9 HAND DEFORMITY 6443 0.7264
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]